The US Food and Drug Administration once again includes in its regulatory agenda update a timeline for publishing a proposed rule to facilitate novel Rx-to-OTC switches. But for the first time the agency includes the change as part of “significant regulatory actions” in its plans.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?